[Identification of patients at high risk of cancer after a venous thromboembolic disease]

J Mal Vasc. 2013 May;38(3):172-7. doi: 10.1016/j.jmv.2013.02.001. Epub 2013 Mar 26.
[Article in French]

Abstract

Objective: Assessment of cancer screening in the context of venous thromboembolic disease (VTE) remains controversial. We tried to characterize a population at high risk of developing cancer among patients suffering from VTE.

Method: We conducted a retrospective ancillary case-control study among patients with VTE who later had a positive diagnosis of cancer. We assessed the association of cancer with characteristic features of VTE and with the results for four biological markers.

Results: Our population included 142 patients (53% men, median age 71 years). Two years after VTE, 24 patients (17%) had cancer. Median values for D-dimers, fibrin monomers and SP-selectin were significantly higher among patients who developed cancer. Logistic regression enabled us to identify two parameters targeting patients with a high risk of cancer: bilateral venous thrombosis (OR: 4.41, 95%CI: 1.41-13.78, P=0.01) and D-dimers superior to 3.8 μg/mL (OR: 3.68, 95%CI: 1.36-9.94, P=0.01). The information provided by these two characteristics was additive; 58% of patients in our population who had both factors developed cancer.

Conclusion: Bilateral venous thrombosis and D-dimers superior to 3.8 μg/mL are highly associated with carcinoma. This result requires a prospective validation. It could be useful in limiting the screening process to the population most at risk.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Biomarkers
  • Case-Control Studies
  • Cell-Derived Microparticles
  • Early Detection of Cancer*
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis*
  • Humans
  • Male
  • Middle Aged
  • Neoplasms, Unknown Primary / blood
  • Neoplasms, Unknown Primary / complications
  • Neoplasms, Unknown Primary / diagnosis*
  • Neoplasms, Unknown Primary / epidemiology
  • P-Selectin / analysis*
  • Predictive Value of Tests
  • Retrospective Studies
  • Risk Assessment
  • Sensitivity and Specificity
  • Thrombophilia / etiology
  • Time Factors
  • Venous Thromboembolism / etiology*

Substances

  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • P-Selectin
  • fibrin fragment D
  • fibrinmonomer